Alzheimer's & Dementia News and Research

Latest Alzheimer's & Dementia News and Research

Women with epilepsy at risk of infertility

Women with epilepsy may be more likely to experience infertility, according to new research published in the October 12, 2010, print issue of Neurology, the medical journal of the American Academy of Neurology.

12 Oct 2010

Embryonic stem cells used in first trial for spinal cord injury

The first ever patient to receive treatment in a U.S. government approved study involving human embryonic stem cells has been injected with millions of the potentially life saving cells. He is presently being treated at the Shepherd Center in Atlanta. He was partially paralyzed following a spinal cord injury. The center specializes in treating these types of injuries.

11 Oct 2010

COU-AA-301 Phase 3 study demonstrates improvement in CRPC survival rate

Results from a pre-specified interim analysis of a randomized, placebo-controlled Phase 3 study, COU-AA-301, demonstrate that patients treated with the investigational agent abiraterone acetate plus low-dose prednisone/prednisolone showed a significant improvement in overall survival compared to patients treated with prednisone/prednisolone plus placebo.

11 Oct 2010

New experimental vaccine against Alzheimer's disease

Researchers at UT Southwestern Medical Center have created an experimental vaccine against beta-amyloid, the small protein that forms plaques in the brain and is believed to contribute to the development of Alzheimer's disease.

11 Oct 2010

Researchers create experimental vaccine for Alzheimer's disease

11 Oct 2010

AFA quarterly magazine features President Obama as guest columnist

President Obama is featured as a guest columnist in the latest issue of the Alzheimer's Foundation of America's (AFA) quarterly magazine for caregivers of individuals with Alzheimer's disease and related illnesses, care ADvantage. In his column, he outlines important provisions in the Affordable Care Act that are relevant to the Alzheimer's community, such as health insurance, drug coverage and long-term care.

8 Oct 2010

Roskamp to initiate RCP-006 clinical trials for Alzheimer's disease

Today the Roskamp Institute said that it is pleased to announce that it will soon begin clinical trials of RCP-006, a compound found in tobacco, for the treatment of Alzheimer's disease.

8 Oct 2010

Targacept announces top-line results from AZD1446 Phase 2 clinical trial for ADHD

Targacept, Inc. today announced top-line results from a Phase 2 clinical trial of AZD1446 conducted by AstraZeneca in adults with attention deficit/hyperactivity disorder (ADHD).

8 Oct 2010

Elevated levels of iron in brain enhance brain-destroying plaque production in Alzheimer's patients: Research

Massachusetts General Hospital researchers say they have determined how iron contributes to the production of brain-destroying plaques found in Alzheimer's patients.

7 Oct 2010

Cortex secures patent rights for combined use of AMPAKINE and mGluR5 compounds for Fragile X syndrome treatment

Cortex Pharmaceuticals, Inc. announced that the rights to a published patent application entitled, "Pharmacological Modulation of Positive AMPA Receptor Modulator Effects on Neurotrophin Expression", has been licensed exclusively to Cortex from the University of California.

7 Oct 2010

New video PSA may help raise donation for brain research

In its continuing fight to end brain disorders, the American Academy of Neurology Foundation is turning entries submitted to the 2010 Neuro Film Festival into its latest video public service announcement about the need for donations for more research into curing brain disorders.

7 Oct 2010

Microglial inflammation promotes MAPT pathologies

Cells that help to protect the central nervous system may also contribute to pathological changes in the brain. New research, published by Cell Press in the October 7th issue of the journal Neuron, provides mechanistic insight into a link between the immune system and neurodegenerative disorders like Alzheimer's disease that are associated with abnormal accumulation of tau protein.

7 Oct 2010

Congress scientific program to highlight new developments in Parkinson's disease

The 7th International Congress on Mental Dysfunction & Other Non-Motor Features in Parkinson's Disease (MDPD 2010), to be held in Barcelona, December 9 - 12, 2010, aims to provide specialists with the latest developments in the understanding of cognitive and psychiatric aspects of the disease.

7 Oct 2010

NeuroDerm receives $1M grant for development of ND0611 dermal patch for Parkinson's disease

NeuroDerm, Ltd. was informed today that it was awarded a grant of $1M by The Michael J. Fox Foundation for Parkinson's Research. These funds will support the next clinical study with ND0611, a new dermal patch for the treatment of Parkinson's disease, as part of the Foundation's prestigious Clinical Intervention Awards 2010 program. This study will evaluate the safety, tolerability, levodopa pharmacokinetics, and possible clinical benefits of ND0611 in advanced Parkinson's disease patients.

6 Oct 2010

Adeona completes enrollment in Part 2 CopperProof-2 clinical study

Adeona Pharmaceuticals, Inc., announced completion of 100% enrollment in Part 2 of its clinical study, A Prospective, Randomized, Double Blind Trial of a Novel Oral Zinc Cysteine Preparation in Alzheimer's Disease (CopperProof-2).

6 Oct 2010

New hope for patients with brain injury

New neuroscience research by life scientists from UCLA and Australia may potentially help people who have lost their ability to remember due to brain injury or disease.

6 Oct 2010

Xeomin botulinum toxin for cervical dystonia now available in the U.S.

Merz Pharmaceuticals today announced that Xeomin (incobotulinumtoxinA), a new botulinum toxin type A for the treatment of adults with cervical dystonia (CD)or blepharospasm, is now commercially available in the U.S. XEOMIN was approved by the U.S. Food and Drug Administration (FDA) on July 30, 2010.

6 Oct 2010

New biomarker could aid in accurate diagnosis of Alzheimer's disease

A set of proteins found in blood serum shows promise as a sensitive and accurate way to diagnose Alzheimer's disease, researchers at UT Southwestern Medical Center have found as part of a statewide study.

6 Oct 2010

Latino community not aware of Alzheimer's disease: Survey

According to the Alzheimer's Association "Hispanic Perceptions of Alzheimer's Disease" survey, which was funded by MetLife Foundation and released today during National Hispanic Heritage Month, 64 percent of survey respondents felt that the Latino community is not very aware or not at all aware of Alzheimer's disease.

6 Oct 2010

Saneron receives grant to develop safety guidelines for transplanting HUBC cells in Alzheimer's disease

The National Institutes of Health has awarded a three-year, $2.6-million grant to the University of South Florida and Tampa-based biotechnology company Saneron-CCEL Therapeutics, Inc., to establish dosing and safety guidelines for transplanting human umbilical cord blood cells (HUBC) into animal models of Alzheimer's disease.

6 Oct 2010